leadf
logo-loader
viewIntrommune Therapeutics

Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval process

Intrommune Therapeutics CEO Michael Nelson sat down with Proactive's Christine Corrado at the Biotech Showcase 2020 in San Francisco. The New York-based biotechnology company is developing is developing an oral mucosal immunotherapy treatment platform to treat food allergies including peanut allergies.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria Bioscience proves technology works in enhancing oral delivery of...

Lexaria Bioscience (OTCQX:LXRP-CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company has announced that its DehydraTECH technology significantly improved delivery in study animals of representative drugs from two classes of antiviral therapies. Bunka telling...

9 minutes ago

2 min read